Analysis of Peripheral Vision With Two Different IOLs
Effect of an Intraocular Lens With Enhanced Peripheral Vision on Gait Performance: a Pilot Study
1 other identifier
interventional
12
1 country
1
Brief Summary
Analyse the peripheral vision after cataract surgery with a new IOL compared to a standard IOL
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2022
CompletedFirst Submitted
Initial submission to the registry
November 28, 2022
CompletedFirst Posted
Study publicly available on registry
December 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedDecember 6, 2022
November 1, 2022
1 year
November 28, 2022
December 5, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Peripheral vision
Peripheral vision will be assessed via gait analysis and will be compared between both eyes
24 months
Secondary Outcomes (2)
Refraction
24 months
Visual acuity
24 months
Study Arms (1)
Gait analysis
EXPERIMENTALA gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
Interventions
A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
Eligibility Criteria
You may qualify if:
- Pseudophakic patients with an Art 40 IOL in one eye and the standard monofocal ICB00 IOL in the other eye. A larger series of patients was operated in this way at Hanusch hospital in 2021 and 2022 as the department has the strategy of implanting a new IOL that has come to market in only one eye and the standard monofocal IOL in the contralateral eye to reduce potential risks, even though the new IOL had a CE mark and was readily available on the market.
- Surgery should have been at least 1 month prior to study recruitment
- Age 21 or older
- Visual acuity \> 0,8
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Able to walk without walking aids
- Written informed consent prior to commencing study measurements.
You may not qualify if:
- nystagmus or pathologies that might affect patient's fixation or physical handicaps that may decrease gait stability
- any ophthalmic comorbidity that may compromise the visual function or might interfere with the experiments (e.g., macular degeneration, corneal scars, pupil abnormalities, glaucoma)
- reduced contrast sensitivity, binocularity, and stereoscopic vision (e.g., amblyopia, strabismus)
- limitation of age-equivalent gait performance because of neurological, cardio-respiratory or musculoskeletal functional deficits
- pregnancy (pregnancy test will be performed in women of reproductive age)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vienna Institute for Research in Ocular Surgery
Vienna, 1140, Austria
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Oliver Findl, MD
Vienna Institute for Research in Ocular Surgery
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 28, 2022
First Posted
December 6, 2022
Study Start
November 1, 2022
Primary Completion
November 1, 2023
Study Completion
November 1, 2024
Last Updated
December 6, 2022
Record last verified: 2022-11